News

Number of news items returned: 1 to 20 records of 391

"Guarda Group has buyer interest but is focused on boosting revenue - CEO"

11 May 2018

(379 views)

  "Guarda Group has buyer interest but is focused on boosting revenue - CEO   Guarda Group, a Perth-based Australian manufacturer of concrete-cutting ...

Director Briefing with Craig Penty, Guarda Group Holdings

10 May 2018

(427 views)

    Director Briefing with Craig Penty, Guarda Group Holdings   In this Director Briefing, Craig Penty, Managing Director of Guarda Group Holdings Pty ...

Guarda's Enviro Chasing Services update

09 May 2018

(402 views)

Guarda Group Holdings' MD, Craig, Penty, provides this update: "We have been lobbying government in WA for a number of years ...

Dealer Trade goes from strength to strength

30 April 2018

(907 views)

  Dealer Trade Holdings announced that its subsidiary CarRecord has entered into a partnership with Gumtree. Since the integration in late ...

Breakfast Invitation, Lessons and News - Funding Strategies Connect April 2018

30 April 2018

(903 views)

  Breakfast Invitation, Lessons and News - Funding Strategies Connect April 2018   Dear Readers, Welcome to the April 2018 edition of Funding Strategies ...

Mark's lessons on capital raising

27 April 2018

(1154 views)

  Mark's lessons on capital raising: Make sure material arrangements are supported by appropriate documentation; Be flexible on how the investment might be ...

Guarda Group signs up major clients

26 April 2018

(1198 views)

  "Guarda Group signs up major clients   On behalf of Guarda Group Holdings, I am delighted to announce that our Perth based ...

Queensland Small Business Week 2018 - Breakfast

19 April 2018

(1345 views)

Queensland Small Business Week 2018 - Breakfast As part of Queensland Small Business Week 2018, Dr Mark Rainbird and his team ...

OpenPort Announces the Launch of the OEL Foundation to Promote Blockchain Innovation within the Supply Chain Industry

19 April 2018

(1024 views)

"OpenPort Announces the Launch of the OEL Foundation to Promote Blockchain Innovation within the Supply Chain Industry   Hong Kong – April 19, ...

"OpenPort actively seeking investors for blockchain transport technology reverse takeover - CEO"

12 April 2018

(1525 views)

  "OpenPort actively seeking investors for blockchain transport technology reverse takeover - CEO OpenPort, a Hong Kong-based global blockchain transport management technology ...

AqMB Holdings - Director Briefing with Darren Szczepanski

10 April 2018

(1931 views)

  In this Director Briefing, Darren Szczepanski, Managing Director of AqMB Holdings Pty Ltd (AqMB Holdings, the Company) discusses: Innovative water treatment ...

"Cyber Research turns down buyers to build more value ahead of potential exit - CEO"

10 April 2018

(1555 views)

  "Cyber Research turns down buyers to build more value ahead of potential exit - CEO Cyber Research, a private Brisbane, Australia-based ...

"AqMB Holdings ramping up water solutions software revenue ahead of potential trade sale from 2020 - MD"

05 April 2018

(1528 views)

  "AqMB Holdings ramping up water solutions software revenue ahead of potential trade sale from 2020 - MD   AqMB Holdings, a privately ...

"Supply Chain Inefficiencies In Emerging Markets: Is Blockchain The Answer?"

28 March 2018

(1532 views)

"Supply Chain Inefficiencies In Emerging Markets: Is Blockchain The Answer?   By Max Ward, CEO and Founder of OpenPort Emerging markets represent the ...

"Blockchain In Transit: OpenPort Paves New Road to Shipping Traceability and Transparency"

27 March 2018

(1542 views)

  Diamond-Michael Scott Digital Economy Journalist Specializing in Blockchain Technology| Fueling The Advancement of Freedom Through Technology "Blockchain In Transit: OpenPort Paves New ...

OpenPort

20 March 2018

(2212 views)

"Canoe Mining Enters Reverse-Takeover LOI with OpenPort, a Private Placement and Disposition of Assets   NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ...

Easter, Event, Introductions and News - Funding Strategies Connect March 2018

16 March 2018

(2043 views)

    Easter, Event, Introductions and News - Funding Strategies Connect March 2018   Dear Reader, Welcome to Funding Strategies Connect. We have seen a ...

JNCI publication involving CytImmune's CYT-21625

10 March 2018

(2195 views)

  "JNCI publication involving CytImmune's CYT-21625"   "Please find attached [via the link below] an article published in the most recent version of ...

AqMB introduces SupplierLink

08 March 2018

(2122 views)

  AqMB introduces SupplierLink   "Welcome to your virtual marketplace Process designers are busy people. Conferences and trade shows are expensive and the leads ...

"APRA to introduce first prudential standard aimed at tackling growing threat of cyber attacks"

07 March 2018

(2169 views)

"APRA to introduce first prudential standard aimed at tackling growing threat of cyber attacks"   Cyber Research has advised us of another ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625